Physician profile
James Mcphail
NPI 1033616701
$2,648.89
in general payments reported to CMS, 2019-2025
20 companies · $1,892 in 2025
The $1,892 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $89.86 · 2023: $14.39 · 2024: $653 · 2025: $1,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,559.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $615.31 | 2022-2025 | |
| Janssen Biotech, INC. | $368.81 | 2024-2025 | Tremfya, Stelara, Simponi |
| Ardelyx, INC. | $215.98 | 2025 | Ibsrela |
| Madrigal Pharmaceuticals | $174.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $159.15 | 2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $157.09 | 2024-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $127.49 | 2024-2025 | Dupixent |
| Qol Medical, LLC | $118.64 | 2024-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.31 | 2024-2025 | Xifaxan |
| Pfizer INC. | $107.64 | 2024-2025 | |
| Celltrion USA INC. | $88.83 | 2025 | Vegzelma |
| Boston Scientific Corporation | $71.43 | 2024 | |
| Gilead Sciences, INC. | $70.65 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $66.77 | 2025 | Iqirvo |
| Novo Nordisk INC | $50.65 | 2025 | Wegovy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $44.43 | 2024-2025 | Voquezna |
| Evoke Pharma, INC. | $33.38 | 2025 | |
| Olympus America INC. | $29.34 | 2022-2023 | Long Clip |
| Alnylam Pharmaceuticals INC. | $20.39 | 2025 | Givlaari |
| Ironwood Pharmaceuticals, INC | $18.79 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcphail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.